EX-32.1 9 sgmt-20230630xex32d1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Sagimet Biosciences Inc. (the “Company”) for the quarterly period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:

| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 21, 2023 | By: | /s/ David Happel
​ | ​ | David Happel
​ | ​ | President and Chief Executive Officer
​ | ​ | (Principal Executive Officer)

​

​

Date: August 21, 2023 | By: | /s/ Anthony Rimac
​ | ​ | Anthony Rimac
​ | ​ | Chief Financial Officer
​ | ​ | (Principal Financial and Accounting Officer)

​